These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

676 related articles for article (PubMed ID: 27798847)

  • 1. Epigenetics of hematopoiesis and hematological malignancies.
    Hu D; Shilatifard A
    Genes Dev; 2016 Sep; 30(18):2021-2041. PubMed ID: 27798847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetics in the hematologic malignancies.
    Fong CY; Morison J; Dawson MA
    Haematologica; 2014 Dec; 99(12):1772-83. PubMed ID: 25472952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of chromatin modifiers in normal and malignant hematopoiesis.
    Butler JS; Dent SY
    Blood; 2013 Apr; 121(16):3076-84. PubMed ID: 23287864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics in normal and malignant hematopoiesis: An overview and update 2017.
    Goyama S; Kitamura T
    Cancer Sci; 2017 Apr; 108(4):553-562. PubMed ID: 28100030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies.
    Sashida G; Iwama A
    Int J Hematol; 2017 Jan; 105(1):23-30. PubMed ID: 27830540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.
    Nakajima H; Kunimoto H
    Cancer Sci; 2014 Sep; 105(9):1093-9. PubMed ID: 25040794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysine-specific histone demethylases in normal and malignant hematopoiesis.
    Andricovich J; Kai Y; Tzatsos A
    Exp Hematol; 2016 Sep; 44(9):778-782. PubMed ID: 27208808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A primer for epigenetics of hematological malignancies].
    Nakajima H
    Rinsho Ketsueki; 2016; 57(10):1835-1844. PubMed ID: 27725578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetics in Hematological Malignancies.
    Cruz-Rodriguez N; Combita AL; Zabaleta J
    Methods Mol Biol; 2018; 1856():87-101. PubMed ID: 30178247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.
    Zhao A; Zhou H; Yang J; Li M; Niu T
    Signal Transduct Target Ther; 2023 Feb; 8(1):71. PubMed ID: 36797244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA methylation in normal and malignant hematopoiesis.
    Celik H; Kramer A; Challen GA
    Int J Hematol; 2016 Jun; 103(6):617-26. PubMed ID: 26943352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel epigenetic therapies in hematological malignancies: Current status and beyond.
    Gallipoli P; Huntly BJP
    Semin Cancer Biol; 2018 Aug; 51():198-210. PubMed ID: 28782607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic regulation of normal and malignant hematopoiesis.
    Rice KL; Hormaeche I; Licht JD
    Oncogene; 2007 Oct; 26(47):6697-714. PubMed ID: 17934479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of DNA methylation programming on normal and pre-leukemic hematopoiesis.
    Langstein J; Milsom MD; Lipka DB
    Semin Cancer Biol; 2018 Aug; 51():89-100. PubMed ID: 28964938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging concepts of epigenetic dysregulation in hematological malignancies.
    Ntziachristos P; Abdel-Wahab O; Aifantis I
    Nat Immunol; 2016 Sep; 17(9):1016-24. PubMed ID: 27478938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic modifiers in normal and malignant hematopoiesis.
    Haladyna JN; Yamauchi T; Neff T; Bernt KM
    Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations to
    Venugopal K; Feng Y; Shabashvili D; Guryanova OA
    Cancer Res; 2021 Jan; 81(2):254-263. PubMed ID: 33087320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guest editorial: Epigenetics of hematopoiesis and hematological malignancies.
    Iwama A
    Int J Hematol; 2012 Oct; 96(4):403-4. PubMed ID: 23015418
    [No Abstract]   [Full Text] [Related]  

  • 19. The Role of PHF6 in Hematopoiesis and Hematologic Malignancies.
    Eisa YA; Guo Y; Yang FC
    Stem Cell Rev Rep; 2023 Jan; 19(1):67-75. PubMed ID: 36008597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histone deacetylases and epigenetic therapies of hematological malignancies.
    Mercurio C; Minucci S; Pelicci PG
    Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.